TransCode Therapeutics (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. Conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, the study will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population. This trial represents a significant step for TransCode as it seeks to address the unmet medical need in patients with minimal residual disease, a condition where standard imaging cannot detect cancer but molecular markers suggest persistent disease.
TTX-MC138 is designed to target tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. By focusing on this specific biomarker, TransCode aims to intervene early in the metastatic process. The Phase 2a trial will evaluate the safety, tolerability, and preliminary efficacy of TTX-MC138, with the goal of preventing recurrence in colorectal cancer patients who have completed initial treatment but remain at high risk due to persistent circulating tumor DNA. The collaboration with Quantum Leap Healthcare Collaborative, known for its innovative clinical trial platform, underscores the strategic positioning of this trial within the broader oncology landscape.
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The initiation of this Phase 2a trial is a critical milestone for the company as it advances its pipeline and seeks to demonstrate the clinical utility of its RNA-based approach.
For more information, the full press release is available at https://ibn.fm/wuRri. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
